REDUCED RISK IN DRUG DEVELOPMENT
CHORD Therapeutics is dedicated to delivering new therapies for chronic, severe neurological disorders, because the great burden to patients and society of these diseases is the driving force motivating our greatest efforts.
Although this is traditionally perceived as a difficult area, the CRD1 program will dramatically reduce the inherent business risks of drug development.
- The program will take advantage of extensive knowledge of CRD1 including its clinical profile in other diseases.
- The CRD1 program will include development of a unique dosing formulation and route.
- CHORD will work with a group of high-quality contract research organizations chosen for their ability to bring dedicated, focused competencies with high cost- and time-effectiveness.
- Project and scientific management will be led by a core staff of industry-experienced professionals.